ARCUTIS BIOTHERAPEUTICS INC (ARQT)
NASDAQ • Healthcare
$26.54
+$0.92 (+3.6%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About ARCUTIS BIOTHERAPEUTICS INC
Name
ARCUTIS BIOTHERAPEUTICS INC
CEO
Todd Franklin Watanabe
Website
Industry
Healthcare
Year Founded
2016
Employees
354
Arcutis Biotherapeutics, Inc. develops and markets therapies for skin-related diseases and operates as a biotechnology company listed on the NASDAQ under ARQT. In FY2025, the company generated $376.1 million in revenue. Formerly known as Arcutis, Inc., it focuses on dermatology products and pipeline programs built around inflammatory skin conditions.
Fundamentals & Financials
Revenue (TTM)
$463.9M
Net Income (TTM)
$28.5M
EPS (TTM)
$0.22
ROA (TTM)
5.84%
Current Ratio
2.92
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$26.54$25.49 - $26.71
52 Week RangeAvg. Volume$15.1 - $31.771.5M
Market CapP/E Ratio$3.3B120.6
ARQT Headlines
FDA clears ZORYVE cream for children 2+
June 30, 2026
3 min read
Peers & Related Assets
CGONCG ONCOLOGY INC
$76.29-1.1%
XENEXENON PHARMACEUTICALS INC
$63.18+1.3%
TVTXTRAVERE THERAPEUTICS INC
$63.9+0.6%
CELCCELCUITY INC
$93.24+0.9%
IRONDISC MEDICINE INC
$80.2+0.2%
TARSTARSUS PHARMACEUTICALS INC
$71.03+0.6%
CNTACentessa Pharmaceuticals plc
FOLDAmicus Therapeutics, Inc.
LEGNLegend Biotech Corporation
ZLABZai Lab Limited